{Reference Type}: Journal Article
{Title}: Syndecan-1 Levels in Females with Active Rheumatoid Arthritis.
{Author}: Rodriguez-Jimenez NA;Gonzalez-Ponce F;Gamez-Nava JI;Ramirez-Villafaña M;Saldaña-Cruz AM;Ponce-Guarneros JM;Olivas-Flores EM;Macías-Islas MA;Valdivia-Tangarife ER;Jacobo-Cuevas H;Ramos-Estrada LG;Totsuka-Sutto S;Cardona-Muñoz EG;Gonzalez-Lopez L;On Behalf Of The Group For The Assessment Of Prognosis Biomarkers In Autoimmune Disorders ;
{Journal}: J Clin Med
{Volume}: 13
{Issue}: 14
{Year}: 2024 Jul 14
{Factor}: 4.964
{DOI}: 10.3390/jcm13144110
{Abstract}: Background: The relationship between serum glycoprotein syndecan-1 and disease activity in rheumatoid arthritis (RA) is still unknown. This study aimed to evaluate whether serum syndecan-1 concentrations are associated with moderate/severe disease activity. Methods: Study Design: This was a cross-sectional study. Seventy-five adult women with RA were classified into (a) moderate/severe RA based on the disease activity score, using the erythrocyte sedimentation rate (DAS28-ESR ≥ 3.2, n = 50), and (b) RA in remission (DAS28-ESR < 2.6, n = 25). Twenty-five healthy women were taken as the reference group. Syndecan-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). High values of serum syndecan-1 levels (≥24 ng/mL) were used to identify the utility values of this biomarker. Results: The patients with RA had higher levels of syndecan-1 than the controls (p < 0.001). RA patients with active disease had higher syndecan-1 levels than RA patients in remission (57.6 vs. 23.5 ng/mL, respectively; p = 0.002). High syndecan-1 concentrations demonstrated the following utility values for identifying disease activity: sensitivity, 84% (95%CI: 71-93); specificity, 52% (95%CI: 31-72); positive predictive value, 78% (95%CI: 70-84); and negative predictive value, 62% (95%CI: 44-77). Conclusions: High syndecan-1 levels have good sensitivity and positive predictive value for identifying disease activity; however, their specificity is limited. Future prospective studies are needed to assess whether syndecan-1 levels can predict treatment failure in RA.